I assume you are referring to the 1st line trial where ogx-011+tax showed a 6 month improvement over tax alone. I don't believe they ran a similar controlled trial for 2nd line. If I remember correctly the 2nd line PII trial they ran had 011+tax in one arm and 011+another chemo in the other. Since the 011 trial was in 1st line its difficult to compare the outcome of that trial with that of the abiraterone trial.
Market Data 
Markets 
AI
